Our oncology clinico-genomic solution is a combination of two of the most comprehensive clinical and genomic data sets in the oncology space.

By combining Ontada's robust electronic health record (EHR) data with Caris' extensive genomic data, life sciences organizations can answer complex questions that can lead to research breakthroughs, drive next-gen therapeutic development and advance patient care through precision medicine.

Our clinico-genomic solution leverages:

• 6.5 million tests: Caris’ molecular-rich, multimodal database
• 13 quadrillion datapoints: Generated from Caris’ tests
• 2.4 million cancer patient records: Derived from Ontada’s EHR used by The US Oncology Network, the largest community oncology network that treats 1 in 5 U.S. cancer patients
• 80+ tumor types: Covered by Ontada’s data

Common use cases for clinico-genomic solution:

• Identify novel biomarkers that can predict cancer progression, treatment response, and patient stratification
• Identify potential new drug targets facilitating the development of targeted cancer therapies
• Obtain insights to help identify factors for overcoming resistance and improving the efficacy of existing cancer treatments
• Identify molecular signatures that predict cancer patient response to specific oncology therapies, enabling more precise treatment plans
• Stratify patients into distinct subgroups, enabling the tailoring of investigational treatments to individual molecular profiles

Integrating Ontada’s real-world evidence and clinical data with Caris’ genomic and molecular insights helps bridge the gap between research and real-world application, creating a streamlined pathway from research and development to clinical practice that will ultimately benefit patients with faster access to more informed treatment decisions, personalized therapies, clinical trials access and improved outcomes.

To learn more about our multimodal oncology data,
fill out the form and one of our data experts will be in touch.

Read the full press release below.